Open AccessReceptor for Hyaluronan‐mediated Motility and CD44 Expressions in Colon Cancer Assessed by Quantitative Analysis Using Real‐time Reverse Transcriptase‐Polymerase Chain Reaction
Author(s) -
Yamada Yoichi,
Itano Naoki,
Narimatsu Hisashi,
Kudo Takashi,
Hirohashi Setsuo,
Ochiai Atsushi,
Niimi Atsushi,
Ueda Minoru,
Kimata Koji
Publication year - 1999
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1999.tb00846.x
Subject(s) - reverse transcriptase , cd44 , reverse transcription polymerase chain reaction , real time polymerase chain reaction , motility , colorectal cancer , polymerase chain reaction , cancer research , receptor , microbiology and biotechnology , chemistry , cancer , medicine , pathology , biology , messenger rna , biochemistry , cell , gene
Receptor for hyaluronan (HA)‐mediated motility (RHAMM) is a receptor for HA‐mediated motility and its expression is correlated with malignancy of ras‐transformed cells in that binding of HA to this receptor activates their migratory ability. CD44, a cell surface receptor for HA is also implicated in metastatic behavior of some cancer cells. In this study we examined the relationships of cancer progression with mRNA levels of RHAMM, CD44 (all forms), and exon 6 of CD44 using the real‐time reverse transcriptase‐polymerase chain reaction method in specimens of colon cancers at different diagnostic stages from 30 patients. Increased mRNA levels of RHAMM were observed in 29 specimens (97%), CD44s (all forms) in 21 specimens (70%), and its exon 6 in 19 specimens (63%) in comparison with those in the corresponding noncancerous tissue specimens. A statistically significant correlation between RHAMM expression and cancerous specimens at any of Dukes' stages A, B, and C was found, and the overexpression of CD44 mRNAs was confirmed in specimens at Dukes' stage C. Thus, our present study for the first time suggests that RHAMM expression may be a clinically useful indicator of colon cancer.